Ascentage Pharma Group International (HK:6855) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Ascentage Pharma Group International is showcasing promising results from its drug candidates olverembatinib and lisaftoclax at the 2024 American Society of Hematology Annual Meeting. Olverembatinib, a third-generation BCR-ABL inhibitor, and lisaftoclax, a Bcl-2 inhibitor, are being highlighted for their potential in treating various hematologic conditions. This recognition underscores the company’s ongoing advancements in drug development, capturing the interest of investors looking for innovative therapies in the biotech sector.
For further insights into HK:6855 stock, check out TipRanks’ Stock Analysis page.